Details for New Drug Application (NDA): 050299
✉ Email this page to a colleague
NDA 050299 describes NILSTAT, which is a drug marketed by Lederle, Strides Pharma, and Chartwell Molecules, and is included in six NDAs. It is available from one supplier. Additional details are available on the NILSTAT profile page.
The generic ingredient in NILSTAT is nystatin. There are eight drug master file entries for this compound. Forty-one suppliers are listed for this compound. Additional details are available on the nystatin profile page.
The generic ingredient in NILSTAT is nystatin. There are eight drug master file entries for this compound. Forty-one suppliers are listed for this compound. Additional details are available on the nystatin profile page.
Summary for 050299
| Tradename: | NILSTAT |
| Applicant: | Chartwell Molecules |
| Ingredient: | nystatin |
| Patents: | 0 |
Suppliers and Packaging for NDA: 050299
| Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
|---|---|---|---|---|---|---|---|---|
| NILSTAT | nystatin | SUSPENSION;ORAL | 050299 | NDA | Chartwell RX, LLC | 62135-813 | 62135-813-24 | 2 TRAY in 1 BOX (62135-813-24) / 10 CUP in 1 TRAY / 5 mL in 1 CUP (62135-813-05) |
| NILSTAT | nystatin | SUSPENSION;ORAL | 050299 | NDA | Chartwell RX, LLC | 62135-813 | 62135-813-46 | 60 mL in 1 BOTTLE (62135-813-46) |
Profile for product number 001
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | SUSPENSION;ORAL | Strength | 100,000 UNITS/ML **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | ||||
| Approval Date: | Approved Prior to Jan 1, 1982 | TE: | RLD: | Yes | |||||
Complete Access Available with Subscription
